[Results of the treatment of myeloma with a vincristine-melphalan combination].

The authors report the results obtained in a series of 20 multiple myelomas by an association Vincristin-Melphalan with a maximum therapeutic survival of 65 months. The median of survival is established at 27 months. The differences are a function of the initial values of the calcemia, the level of hemoglobin, the percentage of medullary plasmocytosis, but the essential factors appear to be the delay in the treatment, the stage of development established according to Salmon and Durie and particularly the presence or absence of a renal involvement.

[Cyclical chemotherapy of myeloma with cell synchronization: therapeutic trial. Apropos of 13 cases].

The authors report the results obtained from the treatment of 13 cases of myeloma by cyclic chemotherapy (melphalan) applied after cellular synchronization with vincristine. The clinical results (maximum 2 years after treatment) were good in 11 cases out of 13. The following laboratory values quickly returned to normal: sedimentation and calcaemia, but there was little change in the immunoglobulins.